Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients

Détails

Ressource 1Télécharger: serval:BIB_6678FC9642EC.P001 (97.60 [Ko])
Etat: Public
Version: de l'auteur
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_6678FC9642EC
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients
Périodique
Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America
Auteur(s)
Viscoli C., Paesmans M., Sanz M., Castagnola E., Klastersky J., Martino P., Glauser M.
Collaborateur(s)
International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer
ISSN
1058-4838 (Print)
ISSN-L
1058-4838
Statut éditorial
Publié
Date de publication
2001
Volume
32
Numéro
11
Pages
1532-1537
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
Published data have suggested a correlation between antifungal prophylaxis and bacteremia in febrile neutropenia. This correlation was investigated among 3002 febrile neutropenic patients enrolled in 4 trials during 1986-1994. Globally, 1322 patients (44%) did not receive antifungal prophylaxis; 835 (28%) received poorly absorbable antifungal agents and 845 (28%) received absorbable antifungal agents. The rates of bacteremia for these groups were 20%, 26%, and 27%, respectively (P=.0001). In a multivariate model without including antifungal prophylaxis, factors associated with bacteremia were: age, duration of hospitalization, duration of neutropenia before enrollment, underlying disease, presence of an intravenous catheter, shock, antibacterial prophylaxis, temperature, and granulocyte count at onset of fever. When antifungal prophylaxis was included, the adjustment quality of the model improved slightly (P=.05), with an odds ratio of 1.19 (95% confidence interval [CI], 0.92-1.55) for patients receiving nonabsorbable and 1.42 (95% CI, 1.07-1.88) for those who were receiving absorbable antifungal agents. Antifungal prophylaxis with absorbable agents might have an impact on the rate of documented bacteremia in febrile neutropenia. This effect should be confirmed prospectively.
Mots-clé
Antibiotic Prophylaxis/utilization, Antifungal Agents/therapeutic use, Bacteremia/epidemiology, Fever/complications, Leukemia, Myeloid, Acute/complications, Neutropenia/complications, Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications
Pubmed
Web of science
Open Access
Oui
Création de la notice
13/07/2018 9:00
Dernière modification de la notice
25/09/2019 6:09
Données d'usage